Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Oct 26, 2020

SELL
$5.02 - $8.98 $536,015 - $958,848
-106,776 Closed
0 $0
Q2 2020

Jul 27, 2020

BUY
$7.25 - $11.75 $774,126 - $1.25 Million
106,776 New
106,776 $862,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Calamos Advisors LLC Portfolio

Follow Calamos Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.